Literature DB >> 27307054

External validation of the IMPROVE Bleeding Risk Assessment Model in medical patients.

David J Rosenberg, Anne Press, Joanna Fishbein, Martin Lesser, Lauren McCullagh, Thomas McGinn, Alex C Spyropoulos1.   

Abstract

The IMPROVE Bleed Risk Assessment Model (RAM) remains the only bleed RAM in hospitalised medical patients using 11 clinical and laboratory factors. The aim of our study was to externally validate the IMPROVE Bleed RAM. A retrospective chart review was conducted between October 1, 2012 and July 31, 2014. We applied the point scoring system to compute risk scores for each patient in the validation sample. We then dichotomised the patients into those with a score <7 (low risk) vs ≥ 7 (high risk), as outlined in the original study, and compared the rates of any bleed, non-major bleed, and major bleed. Among the 12,082 subjects, there was an overall 2.6 % rate of any bleed within 14 days of admission. There was a 2.12 % rate of any bleed in those patients with a score of < 7 and a 4.68 % rate in those with a score ≥ 7 [Odds Ratio (OR) 2.3 (95 % CI=1.8-2.9), p<0.0001]. MB rates were 1.5 % in the patients with a score of < 7 and 3.2 % in the patients with a score of ≥ 7, [OR 2.2 (95 % CI=1.6-2.9), p<0.0001]. The ROC curve was 0.63 for the validation sample. This study represents the largest externally validated Bleed RAM in a hospitalised medically ill patient population. A cut-off point score of 7 or above was able to identify a high-risk patient group for MB and any bleed. The IMPROVE Bleed RAM has the potential to allow for more tailored approaches to thromboprophylaxis in medically ill hospitalised patients.

Entities:  

Keywords:  Risk Assessment Model; anticoagulants; bleeding risk; medical patients; validation

Mesh:

Year:  2016        PMID: 27307054     DOI: 10.1160/TH16-01-0003

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  14 in total

1.  Risk-assessment models for VTE and bleeding in hospitalized medical patients: an overview of systematic reviews.

Authors:  Andrea J Darzi; Allen B Repp; Frederick A Spencer; Rami Z Morsi; Rana Charide; Itziar Etxeandia-Ikobaltzeta; Kenneth A Bauer; Allison E Burnett; Mary Cushman; Francesco Dentali; Susan R Kahn; Suely M Rezende; Neil A Zakai; Arnav Agarwal; Samer G Karam; Tamara Lotfi; Wojtek Wiercioch; Reem Waziry; Alfonso Iorio; Elie A Akl; Holger J Schünemann
Journal:  Blood Adv       Date:  2020-10-13

2.  International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease.

Authors:  Pablo A Olivera; Stephane Zuily; Paulo G Kotze; Veronique Regnault; Sameer Al Awadhi; Peter Bossuyt; Richard B Gearry; Subrata Ghosh; Taku Kobayashi; Patrick Lacolley; Edouard Louis; Fernando Magro; Siew C Ng; Alfredo Papa; Tim Raine; Fabio V Teixeira; David T Rubin; Silvio Danese; Laurent Peyrin-Biroulet
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-08-27       Impact factor: 46.802

3.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.

Authors:  Holger J Schünemann; Mary Cushman; Allison E Burnett; Susan R Kahn; Jan Beyer-Westendorf; Frederick A Spencer; Suely M Rezende; Neil A Zakai; Kenneth A Bauer; Francesco Dentali; Jill Lansing; Sara Balduzzi; Andrea Darzi; Gian Paolo Morgano; Ignacio Neumann; Robby Nieuwlaat; Juan J Yepes-Nuñez; Yuan Zhang; Wojtek Wiercioch
Journal:  Blood Adv       Date:  2018-11-27

4.  Anti-coagulant and anti-platelet therapy in the COVID-19 patient: a best practices quality initiative across a large health system.

Authors:  Ryan A Watson; Drew M Johnson; Robin N Dharia; Geno J Merli; John U Doherty
Journal:  Hosp Pract (1995)       Date:  2020-06-09

5.  Do Inpatients Receive Risk-Based Prophylactic Treatment for Thrombotic Events?

Authors:  Armin Nemani; Constantin von Zur Mühlen; Friederike Steffen; Johannes Schulte; Christoph Bode; Marvin Krohn-Grimberghe
Journal:  Clin Appl Thromb Hemost       Date:  2021 Jan-Dec       Impact factor: 2.389

Review 6.  Bleeding risk assessment for venous thromboembolism prophylaxis.

Authors:  Maria Chiara Chindamo; Marcos Arêas Marques
Journal:  J Vasc Bras       Date:  2021-04-28

Review 7.  Platelet Count and Bleeding in Patients Receiving Anticoagulant Therapy for Venous Thromboembolism: Lesson from the RIETE Registry.

Authors:  Pierpaolo Di Micco; Manuel Monreal
Journal:  J Blood Med       Date:  2019-12-31

8.  A Prospective Observational Cohort of Clinical Outcomes in Medical Inpatients prescribed Pharmacological Thromboprophylaxis Using Different Clinical Risk Assessment Models(COMPT RAMs).

Authors:  Nibal Chamoun; Stephanie Matta; Sandrine Sarine Aderian; Rami Salibi; Pascale Salameh; Gaby Tayeh; Elie Haddad; Hady Ghanem
Journal:  Sci Rep       Date:  2019-12-04       Impact factor: 4.379

9.  Post-discharge thrombosis and bleeding in medical patients: A novel risk score derived from ubiquitous biomarkers.

Authors:  Scott C Woller; Scott M Stevens; Masarret Fazili; James F Lloyd; Emily L Wilson; Gregory L Snow; Joseph R Bledsoe; Benjamin D Horne
Journal:  Res Pract Thromb Haemost       Date:  2021-07-07

10.  Pragmatic study of a thromboprophylaxis algorithm in critically ill patients with SARS-COV-2 infection.

Authors:  Maurizio Fattorutto; Yves Bouckaert; Jonathan Brauner; Stéphane Franck; Fabrice Bouton; Danielle Heuse; Charlotte Bouckaert; Arnaud Bruyneel
Journal:  J Thromb Thrombolysis       Date:  2021-06-26       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.